newsfilter
← Latest News
Business Wire·

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on